Deals

Lycia Therapeutics Files For Nasdaq IPO With No Revenue In 2026 After Eli Lilly Ended Its Deal

The filing reports a $19.2 million first-half loss, and it leaves the share count, price range and offering size blank.

Lycia Therapeutics, a South San Francisco biotech, filed an S-1 on Monday to go public on the Nasdaq Global Market under the proposed symbol LYCA. The filing shows a net loss of $19.2 million for the six months ended June 30, 2026, and no collaboration revenue in that period.

The filing says the company expects more LCA-0061 data, including from food allergy patients, but the timing is left blank in the document.

Sources

S-1 — Lycia Therapeutics, Inc. — SEC EDGAR

IREN Budgets $25 Billion To $30 Billion For Its AI Build-Out — More Than Its Entire $13.9 Billion Market Value

IREN stock has plunged 54% from highs earlier this year.

Arista CEO Jayshree Ullal's Trusts Sold $21.1 Million Of Stock Under A Plan Set In November 2025

A Form 4 shows three trust accounts sold 96,992 shares on Wednesday, the fourth sale in her five latest filings.

Bambusa Files For Nasdaq IPO With $41.1 Million Loss, No Revenue And A Going-Concern Warning

The Boston antibody developer's S-1 leaves price and share count blank and says $71.5 million in cash may not last a year.

Standard BioTools Holders Would Own About 16% Of Treeline Combination, Amended S-4 Shows

The second amended filing sets an exchange ratio range, a 12-seat board and a $2.5 billion Treeline value against $460 million for Standard BioTools.

Sources

Read more

IREN Budgets $25 Billion To $30 Billion For Its AI Build-Out — More Than Its Entire $13.9 Billion Market Value

Arista CEO Jayshree Ullal's Trusts Sold $21.1 Million Of Stock Under A Plan Set In November 2025

Bambusa Files For Nasdaq IPO With $41.1 Million Loss, No Revenue And A Going-Concern Warning

Standard BioTools Holders Would Own About 16% Of Treeline Combination, Amended S-4 Shows